The close that opens blue sky
Merck just did the thing most traders wait weeks for. It closed above July’s high of $135.05, the prior all-time high, and followed through the next session at $135.84. That close is the trigger. Stop sits at $125.92, under the early-August pullback lows that launched this move. First target is $149.84, about 1.4:1. If you keep a runner, the full Fibonacci extension at $207 is about 7:1. This is a level-based idea, not a prediction.
The technical setup: a confirmed close through the old ceiling
From the late-2025 lows, Merck has been building a higher-high, higher-low structure. July 28 tagged $135.05 and failed to close through it. That wick became the prior all-time high and the obvious ceiling.
August 13 closed at $135.55. August 14 held it at $135.84 and printed a new high at $135.97. Two daily closes above the old ATH is the confirmation. A wick is not.
Above $135.05 there is no prior supply on the chart. That is what blue sky means. Price is not fighting old sellers. It is walking into open air.
The stop at $125.92 sits just under the August 3-4 pullback lows near $126.22. Hit that and the higher low that launched the breakout is gone. You are back inside the prior range.
The first target at $149.84 is not a guess. The first Fibonacci extension off this swing sits at $149.76. A measured 1.4:1 from the $125.92 stop lands in the same area. Two independent methods, one number.
The $207 stretch is the 161.8% extension of the larger swing that puts the 38.2% retracement at $90.75 and the 0% line at $135.04. That is a runner target, not the first take-profit.
The fundamental case: growth is still there after you strip the one-time charge
Q2 printed $16.6 billion in sales, up 5% year over year and 4% excluding FX (Merck Q2 2026 earnings release). GAAP EPS was a $0.54 loss. Non-GAAP was a $0.13 loss. Both include a $2.31-per-share charge for the Terns acquisition. That is a balance-sheet event, not a demand problem.
The KEYTRUDA family, KEYTRUDA plus KEYTRUDA QLEX, did $8.37 billion, up 5% (Merck Q2 2026 earnings release). WINREVAIR did $588 million, up 75%. WELIREG grew 67% to $271 million. CAPVAXIVE grew 40% excluding FX to $184 million. OHTUVAYRE, from the Verona deal, added $204 million. Animal Health grew 5% excluding FX to $1.78 billion. GARDASIL held at $1.17 billion.
Management raised and narrowed full-year sales guidance to $66.3 billion to $67.3 billion (Merck Q2 2026 earnings release). The EPS guide of $2.66 to $2.76 looks ugly on the surface because it includes the Terns charge. Strip that and you are looking at a company that still grew the top line and raised the sales range.
July added a real new product. The FDA approved LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor (Merck LIPFENDRA approval) (FDA). That is a cardiometabolic franchise, not another oncology line extension.
The next dated catalyst is the WINREVAIR HYPERION label-update PDUFA on September 21, 2026 (Merck Q2 2026 earnings call). Q3 earnings land October 29. Those two dates are why this is a swing, not a hold-and-hope position.
Doing the math: $9.92 of risk, two ways to get paid
Entry at the August 14 close of $135.84 against a $125.92 stop is $9.92 of risk per share.
First target $149.84 is $14.00 of reward. That is 1.4:1. Close enough to the clean 1.5:1 on the chart that the trade still earns its keep.
The $207 extension is $71.16 of reward, or about 7.2:1, against the same stop.
Do not size those two the same way. Take most of the position off into $149.84. If you keep a runner toward $207, cut the size and trail the stop. $207 is a technical extension, not a Street consensus number. Treat it like leaving a smaller plate on the table after the main course, not like the whole meal.
Thesis invalidation: what would prove this wrong
Technical invalidation: a daily close back below $135.05 says the breakout failed. The $125.92 stop is the hard line. If that prints, the August higher-low is gone and you are guessing.
Fundamental invalidation: a stall in KEYTRUDA family demand, a WINREVAIR miss or a disappointing September 21 PDUFA, a cut to the $66.3-$67.3 billion sales range, or a failed pipeline readout. October 29 earnings is a flagged risk window. If you are still in the trade into that print, size like you expect volatility, not like you expect a gift.
What this means for how you’d actually trade it
The trigger already fired. You are not waiting for a close. You are deciding whether to take the current price or wait for the first pullback that still holds above $135.05.
If Merck gaps away from $135.84, do not chase. A first pullback that holds the old ATH is a cleaner fill than buying thin air. If price is still sitting on the breakout, the August 14 close is a valid fill.
Risk the same dollar amount you would on any other short-term swing. The 7:1 runner is optional. The 1.4:1 first target is the trade. For the full sizing process, use the Risk Management Mastery series.
Takeaway: The close above $135.05 is the whole trade. Above it, Merck is in blue sky with a defined $149.84 first target and a $207 runner if you want it. Below it, the breakout failed. You do not need $207 to be right. You need a defined risk, a first target, and the discipline to take the first one.
References
- Merck & Co., Inc. Announces Second-Quarter 2026 Financial Results – Merck
- Our Q2 2026 Financial Results – Merck
- Investor Relations – Merck
- MRK Q2 2026 Earnings Call Transcript – Merck
- Merck’s LIPFENDRA (enlicitide) Is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA – Merck
- FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol – U.S. Food and Drug Administration
- Merck Completes Acquisition of Terns Pharmaceuticals, Inc. – Merck
- Merck Announces Phase 3 HYPERION Study of WINREVAIR Met Primary Endpoint – Merck
- Q2 2026 Earnings Call – Merck
